[go: up one dir, main page]

PE20080424A1 - Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas - Google Patents

Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Info

Publication number
PE20080424A1
PE20080424A1 PE2007001088A PE2007001088A PE20080424A1 PE 20080424 A1 PE20080424 A1 PE 20080424A1 PE 2007001088 A PE2007001088 A PE 2007001088A PE 2007001088 A PE2007001088 A PE 2007001088A PE 20080424 A1 PE20080424 A1 PE 20080424A1
Authority
PE
Peru
Prior art keywords
maleate
trifluorometil
metoxy
quinolin
difluorophenyl
Prior art date
Application number
PE2007001088A
Other languages
English (en)
Inventor
Xiaoming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vicenzo Liotta
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080424A1 publication Critical patent/PE20080424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DE LAS SALES MALEATO, TOSILATO, FUMARATO Y OXALATO DEL COMPUESTO 5-(1(S)-AMINO-2-HIDROXIETIL)-N-[(2,4-DIFLUOROFENIL)-METIL]-2-[8-METOXI-2-(TRIFLUOROMETIL)-5-QUINOLIN]-4-OXAZOLCARBOXAMIDA DE FORMULA (I), EN DONDE LA SAL MALEATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 6,5; 7,5; 21,2; 27,2; ENTRE OTROS; LA SAL TOSILATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 5,2; 12,5; 20,0; 26,3; ENTRE OTROS; LA SAL FUMARATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 8,0; 19,9; 22,5; 25,6; ENTRE OTROS. SE REFIERE TAMBIEN A PROCEDIMIENTOS DE PREPARACION DE DICHAS FORMAS CRISTALINAS. DICHO COMPUESTO ES UN INHIBIDOR DE LA FOSFODIESTERASA 4 (PDE-4) SIENDO UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2007001088A 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas PE20080424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
PE20080424A1 true PE20080424A1 (es) 2008-04-28

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001088A PE20080424A1 (es) 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Country Status (11)

Country Link
US (1) US7956189B2 (es)
EP (1) EP2069337A1 (es)
JP (3) JP2010500406A (es)
CN (1) CN101522671A (es)
AR (1) AR062373A1 (es)
CA (1) CA2660703A1 (es)
CL (1) CL2007002366A1 (es)
MX (1) MX2009001770A (es)
PE (1) PE20080424A1 (es)
TW (1) TW200819446A (es)
WO (1) WO2008021271A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) * 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116009A1 (en) * 2004-05-18 2005-12-08 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors

Also Published As

Publication number Publication date
WO2008021271A1 (en) 2008-02-21
US20080108818A1 (en) 2008-05-08
CA2660703A1 (en) 2008-02-21
US7956189B2 (en) 2011-06-07
CN101522671A (zh) 2009-09-02
EP2069337A1 (en) 2009-06-17
TW200819446A (en) 2008-05-01
JP2010500406A (ja) 2010-01-07
JP2013032394A (ja) 2013-02-14
MX2009001770A (es) 2009-02-25
AR062373A1 (es) 2008-11-05
CL2007002366A1 (es) 2008-03-14
JP2012176989A (ja) 2012-09-13

Similar Documents

Publication Publication Date Title
PE20080424A1 (es) Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
TR201904655T4 (tr) Piridilaminoasetik asit bileşiği.
EA201591978A1 (ru) 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил)- карбамимидоил)пиразин-2-карбоксамид
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
AR062927A1 (es) 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
RU2010128512A (ru) Гетероциклические ингибиторы мек и способы их применения
ECSP077356A (es) Forma termodinámicamente estable de una sal tosilato
GEP201706735B (en) Kinase inhibitors
JP2012530705A5 (es)
JP2011518833A5 (es)
PE20121337A1 (es) Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
CO6270323A2 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro- 1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico y metodos para su uso
JP2008513510A5 (es)
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
JP2012500205A5 (es)
PE20071068A1 (es) Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
CO6270221A2 (es) "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".
JP2008542390A5 (es)
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica

Legal Events

Date Code Title Description
FC Refusal